Chemotherapie des HCC
| Referenz | Phase | Regime | n | PR + CR | SD (%) | medianes Überleben |
| Sciarrino 1985 (6) | retrospektiv | Doxorubicin | 109 | 10 | – | 13% nach 1 Jahr |
| Lai 1988 (1) | randomisiert | Doxorubicin vs. | 60 | N/A | – | 10,6 Wochen |
| BSC | 46 | N/A | – | 7,5 Wochen | ||
| Lee 2004 (3) | II | Doxorubicin + Cisplatin | 37 | 19 | 16 | 7,3 Monate |
| Yeo 2005 (8) | III | Doxorubicin vs. | 94 | 10 | 39 | 6,8 Monate |
| PIAF (Cisplatin, Doxorubicin, 5-FU, IFN-a) | 94 | 20 | 37 | 8,7 Monate | ||
| Yang 2000 (7) | II | Gemcitabin | 28 | 18 | 25 | 4,7 Monate |
| Patt 2004 (5) | II | Capecitabin | 37 | 11 | 11 | 10,1 Monate |
| Louafi 2007 (4) | II | Gemcitabin + Oxa[iplatin | 32 | 18 | 58 | 11,5 Monate |
| Boige 2007 (2) | II | Capecitabin + Oxa[ip[atin | 50 | 6 | 58 | 9,3 Monate |
Chemotherapie
Quellen
Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.
Cancer 1988; 62: 479-486
2.) Boige V, et al.:
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Br J Cancer 2007; 97: 862-7.
3.) Lee J, et al.:
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Cancer Chemother Pharmacol 2004; 54: 385-9o
4.) Louafi S, et al.:
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
Cancer 2007;109:1384-90
5.) Patt YZ, et al.:
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Cancer 2004;101: 578-86.
6.) Sciarrino E, et al.:
Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.
Cancer 1985; 56: 2751-5
7.) Yang TS, et al.:
Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
Cancer 2000; 89: 750-6
8.) Yeo W et al.:
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha 2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
J Natl Cancer Inst 2005; 97:1532
